MaxCyte to Report Fourth Quarter and Full Year 2024 Financial
Results on March 11, 2025, and Participate in Upcoming Investor
Conference
ROCKVILLE, MD,
February 7, 2025 - MaxCyte, Inc., (NASDAQ: MXCT; LSE:
MXCT), a leading, cell-engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell therapeutics, today announced that it will release financial
results for the fourth quarter and full year 2024 after the U.S.
market close on Tuesday, March 11th, 2025. Company management will
host a conference call to discuss financial results at 4:30 p.m.
Eastern Time.
Earnings Conference
Call Details
Investors interested in listening to the conference
call are required to
register online. It is recommended to register at least a day
in advance. A live and archived webcast of the event will be
available on the "Events" section of the MaxCyte website at
https://investors.maxcyte.com/.
Company management will also participate in the
following investor conference:
·
45th Annual TD Cowen Healthcare Conference
Fireside Chat on Monday, March 3rd at
10:30a.m. ET
A live and archived webcast of the Cowen fireside
chat will be available on the "Event" section of the MaxCyte
investor relations website at https://investors.maxcyte.com/.
About
MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 25 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been designed
to support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more
at maxcyte.com and
follow us on X and LinkedIn.
MaxCyte
Contacts:
US IR
Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media
Relations
Spectrum Science
Jordan Vines
+1 540-629-3137
jvines@spectrumscience.com
Nominated Adviser
and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR
Adviser
ICR Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
